Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

Janssen receives FDA complete response letter for XARELTO sNDA

Janssen Research & Development, LLC (Janssen R&D) announced today the U.S. Food and Drug Administration (FDA) issued a complete response letter regarding a supplemental New Drug Application (sNDA) for XARELTO (rivaroxaban) for the reduction of the risk of secondary cardiovascular events in patients with acute coronary syndrome (ACS).

22 Jun 2012

Aeterna Zentaris announces perifosine Phase 1 trial on neuroblastoma

Aeterna Zentaris Inc. today announced that Phase 1 trial results for its oral PI3K/Akt inhibitor, perifosine, showed the drug's activity against chemo-resistant and radio-resistant neuroblastoma, while allowing good quality of life and sparing vital organs. Neuroblastoma is a type of childhood cancer which usually begins in nerve tissues.

22 Jun 2012

Teva launches Olanzapine and Fluoxetine Capsules for treatment of depression

Teva Pharmaceutical Industries Ltd. announced today the launch of Olanzapine and Fluoxetine Capsules USP 6 mg/25 mg, 12 mg/25 mg, 6 mg/50 mg, and 12 mg/50 mg, the Company's generic equivalent of Symbyax.

22 Jun 2012

Even small-stage oral SCC metastases impact prognosis

The presence of even small tumor-cell deposits in the lymph nodes of patients with early oral and oropharyngeal squamous cell carcinoma reflects a potential for the primary tumor to metastasize, report researchers in Head and Neck.

21 Jun 2012

Bowel disturbance common until the end

Patients treated by palliative care services experience bowel disturbances until the end of life, with severe problems increasing as death approaches, report Australian researchers.

21 Jun 2012

Congress considers Medicare, FDA proposals

The Senate Finance Committee is once again talking deficit reduction and Medicare as both houses are "poised" to pass an FDA bill.

21 Jun 2012

GBM patients with CNP subtype may have less aggressive subtype of cancer

A diagnosis of glioblastoma multiforme (GBM) is generally a death sentence, but new research from the University of Wisconsin-Madison lab of Dr. John Kuo shows that at least one subtype is associated with a longer life expectancy. This discovery could help with better patient prognoses and lead to targeted drug treatments for GBM subtypes.

21 Jun 2012

Value of pathology review highlighted in node-negative breast cancer

Secondary pathology review results in significant changes in diagnosis and treatment for women with node-negative breast cancer, Canadian researchers report.

20 Jun 2012

Screening reduces colorectal cancer death not development risk

Screening for colorectal cancer by testing for fecal occult blood reduces the risk for death from this type of cancer, study results show.

20 Jun 2012

Sufficient cancer pain relief may mean frequent follow up

US study findings show that just over half of cancer patients receiving outpatient palliative care who have mild or moderate pain intensity at initial consultation, report an increase to moderate or severe pain intensity by first follow up.

20 Jun 2012

Antimicrobial exposure may increase risk of allergies in children

Exposure to common antibacterial chemicals and preservatives found in soap, toothpaste, mouthwash and other personal-care products may make children more prone to a wide range of food and environmental allergies, according to new research from Johns Hopkins Children's Center.

20 Jun 2012

Positive results from Zalicus Z944 Phase 1 SAD clinical study for chronic inflammatory pain

Zalicus Inc., a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases, announced that it is has successfully completed a Phase 1 single ascending dose (SAD) clinical study with Z944, its novel, oral, T-type calcium channel blocker.

19 Jun 2012

AstraZeneca, Rigel enter global license agreement for R256 inhaled JAK inhibitor to treat chronic asthma

AstraZeneca and Rigel Pharmaceuticals Inc. today announced an exclusive worldwide license agreement for the global development and commercialization of R256, Rigel's inhaled JAK inhibitor shown to inhibit IL-13 and IL-4 signalling, which is being investigated as a treatment for moderate to severe chronic asthma. In preclinical research, R256 has been shown to reduce airway inflammation and improve lung function.

19 Jun 2012

Bisphosphonate benefit for breast cancer yet to be proven

Older patients with breast cancer may benefit from adjuvant treatment with oral bisphosphonates, but further studies are needed before general application in the breast cancer population, say researchers.

19 Jun 2012

e-Therapeutics commences enrollment in ETS2101 phase I trial for brain cancer

e-Therapeutics plc announces the start of the first clinical trial evaluating its compound ETS2101 as a treatment for cancer. The phase I trial is enrolling patients with primary brain cancer (glioma) or cancer that has spread to the brain from other sites.

19 Jun 2012

Allergy risk in children linked to antibacterials in personal-care products

Exposure to common antibacterial chemicals found in soap, toothpaste, mouthwash and other personal-care products may make children more prone to a wide range of food and environmental allergies, according to new research from Johns Hopkins Children’s Center.

19 Jun 2012

FORMA, TD2 leverage synergistic capabilities to jointly develop transformative cancer therapies

FORMA Therapeutics and TGen Drug Development (TD2) today announced an agreement to jointly develop transformative cancer therapies, leveraging the synergistic capabilities of both organizations.

19 Jun 2012

Delcath includes second-generation hemofiltration cartridge in chemosaturation system EAP

Delcath Systems, Inc. today announced that the Company has amended its Investigational New Drug (IND) application and its Expanded Access Program (EAP) to include the use of the second-generation hemofiltration cartridge of the Company's proprietary chemosaturation system.

19 Jun 2012

New clinical data for ZEVALIN Injection for intravenous use presented at 17th EHA Congress

Spectrum Pharmaceuticals, Inc., a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology and hematology, today announced new clinical data presented in an oral presentation for ZEVALIN (ibritumomab tiuxetan) Injection for intravenous use at the 17th Congress of the European Hematology Association (EHA).

19 Jun 2012

Study on identification of novel stem cell population in neuroblastoma to be presented at ANR conference

Dr. Eugene Kim, a pediatric surgeon with Texas Children's Cancer Center and assistant professor of surgery at Baylor College of Medicine (BCM), and Dr. Jason Shohet, chair of the Neuroblastoma Research Program at Texas Children's Cancer Center and associate professor in the Section of Hematology-Oncology at BCM, will speak at the Advances in Neuroblastoma Research (ANR) conference about the identification of a novel stem cell population in neuroblastoma.

19 Jun 2012